1874276-76-2

1874276-76-2 structure

Name: Darovasertib (LXS-196)
Chemical Name: NVP-LXS196
CAS Number: 1874276-76-2
Molecular Formula: C₂₂H₂₃F₃N₈O
Molecular Weight: 472.466
Catalog: Signaling Pathways Epigenetics PKC
Create Date: 2018-07-06 23:32:32
Modify Date: 2026-07-02 18:08:00
LXS196 is a potent and orally active protein kinase C (PKC) inhibitor under Phase I clinical trials for the treatment of uveal melanoma.

Name	NVP-LXS196
Synonyms	LXS196,IDE196 Dovasertib (LXS-196) 3-amino-N-(3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl)-6-(3-(trifluoromethyl)pyridin-2-yl)pyrazine-2-cboxamide LXS-196 LXS196 Dovasertib, 10 mM in DMSO EOS-61826 Dovasertib Protein kinase C,Dovasertib,IDE196,LXS-196,Inhibitor,PKC,LXS 196,IDE-196,IDE 196,inhibit 2-Pyrazinecboxamide, 3-amino-N-[3-(4-amino-4-methyl-1-piperidinyl)-2-pyridinyl]-6-[3-(trifluoromethyl)-2-pyridinyl] NVP-LXS196; NVPLXS196; NVP LXS196; LXS-196; LXS 196; LXS196; LXS-196 LXS-196 (NVP-LXS196) IDE-196 3-Amino-N-[3-(4-amino-4-methyl-1-piperidinyl)-2-pyridinyl]-6-[3-(trifluoromethyl)-2-pyridinyl]-2-pyrazinecarboxamide

Description	LXS196 is a potent and orally active protein kinase C (PKC) inhibitor under Phase I clinical trials for the treatment of uveal melanoma.
Related Catalog	Signaling Pathways >> Epigenetics >> PKC Signaling Pathways >> TGF-beta/Smad >> PKC Research Areas >> Cancer
Target	PKC
In Vitro	Upon oral administration, protein kinase C inhibitor LXS196 binds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival[1].
References	[1]. Protein Kinase C Inhibitor LXS196